J. C. Barrett, B. Fry, J. Maller, and M. J. Daly, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, vol.21, pp.263-265, 2005.

J. Y. Blay, A. Italiano, I. Ray-coquard, C. A. Le, F. Duffaud et al., Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program, BMC Cancer, vol.13, p.64, 2013.

I. Cass, R. L. Baldwin, T. Varkey, R. Moslehi, S. A. Narod et al., Improved survival in women with BRCA-associated ovarian carcinoma, Cancer, vol.97, issue.9, pp.2187-2195, 2003.

P. O. Chappuis, J. Goffin, N. Wong, C. Perret, P. Ghadirian et al., A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer, J Med Genet, vol.39, issue.8, pp.608-610, 2002.

F. Chibon, P. Lagarde, S. Salas, G. Perot, V. Brouste et al., Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity, Nat Med, vol.16, issue.7, pp.781-787, 2010.

G. Damia, S. Silvestri, L. Carrassa, L. Filiberti, G. T. Faircloth et al., Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways, Int J Cancer, vol.92, issue.4, pp.583-588, 2001.

G. D. Demetri, S. P. Chawla, V. Mm, P. Ritch, L. H. Baker et al., Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules, J Clin Oncol, vol.27, issue.25, pp.4188-4196, 2009.

E. Erba, D. Bergamaschi, L. Bassano, G. Damia, S. Ronzoni et al., Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action, Eur J Cancer, vol.37, issue.1, pp.97-105, 2001.

R. Garcia-carbonero, J. G. Supko, J. Manola, M. V. Seiden, D. Harmon et al., Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy, J Clin Oncol, vol.22, issue.8, pp.1480-1490, 2004.

J. R. Goffin, P. O. Chappuis, L. R. Begin, N. Wong, J. S. Brunet et al., Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data, Cancer, vol.97, issue.3, pp.527-536, 2003.

A. B. Herrero, C. Martin-castellanos, M. E. Gago, F. Moreno, and S. , Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin, Cancer Res, vol.66, issue.16, pp.8155-8162, 2006.

M. S. Huen, S. M. Sy, and J. Chen, BRCA1 and its toolbox for the maintenance of genome integrity, Nat Rev Mol Cell Biol, vol.11, issue.2, pp.138-148, 2010.

A. Italiano, A. Laurand, A. Laroche, P. Casali, R. Sanfilippo et al., ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma, Cancer, vol.117, issue.15, pp.3445-3456, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00837859

H. T. Kim, J. E. Lee, E. S. Shin, Y. K. Yoo, J. H. Cho et al., Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy, J Clin Oncol, vol.26, issue.36, pp.5972-5979, 2008.

Y. M. Kirova, D. Stoppa-lyonnet, A. Savignoni, B. Sigal-zafrani, N. Fabre et al., Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breastconserving surgery and radiotherapy, Eur J Cancer, vol.41, issue.15, pp.2304-2311, 2005.

L. Cesne, A. Blay, J. Y. , J. I. Van, O. A. Verweij et al., Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial, J Clin Oncol, vol.23, issue.3, pp.576-584, 2005.

N. Martinez, M. Sanchez-beato, A. Carnero, V. Moneo, J. C. Tercero et al., Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients, Mol Cancer Ther, vol.4, issue.5, pp.814-823, 2005.

C. G. Murphy and M. E. Moynahan, BRCA gene structure and function in tumor suppression: a repair-centric perspective, Cancer J, vol.16, issue.1, pp.39-47, 2010.

P. Schoffski, M. Taron, J. Jimeno, F. Grosso, R. Sanfilipio et al., Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study, Eur J Cancer, vol.47, issue.7, pp.1006-1012, 2011.

H. J. Shim, J. Y. Yun, J. E. Hwang, W. K. Bae, S. H. Cho et al., BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin, Cancer Sci, vol.101, issue.5, pp.1247-1254, 2010.

D. G. Soares, A. E. Escargueil, V. Poindessous, A. Sarasin, G. A. De et al., Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743, Proc Natl Acad Sci, vol.104, issue.32, pp.13062-13067, 2007.

Y. Takebayashi, P. Pourquier, D. B. Zimonjic, K. Nakayama, S. Emmert et al., Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair, Nat Med, vol.7, issue.8, pp.961-966, 2001.

P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, vol.92, issue.3, pp.205-216, 2000.

A. Yovine, M. Riofrio, J. Y. Blay, E. Brain, J. Alexandre et al., Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients, J Clin Oncol, vol.22, issue.5, pp.890-899, 2004.